Original Articles
Vol. 19 No. 2 (2025)
Metformin’s therapeutic potential in adenomyosis: insights from interleukin 8 level
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 4 February 2025
Accepted: 23 February 2025
Accepted: 23 February 2025
1373
Views
374
Downloads
0
HTML
Authors
Adenomyosis is a gynecological disorder characterized by the invasion of endometrial tissue into the myometrium, leading to chronic inflammation and pelvic pain. Interleukin 8 (IL-8) plays a key role in inflammation and pain sensitization in adenomyosis. Metformin, an antidiabetic agent, exerts anti-inflammatory effects by activating adenosine monophosphate-activated protein kinase, inhibiting IL-8 production, and reducing inflammatory cell infiltration. This cohort-prospective study evaluates the effects of metformin on IL-8 levels and pain in adenomyosis patients. This cohort-prospective study in Makassar, Indonesia, included 40 women diagnosed with adenomyosis via physical examination and ultrasound examination in a polyclinic at Hasanuddin University Teaching Hospital. Participants were divided into two groups: 20 received metformin 500 mg and ibuprofen 400 mg every 8 hours for 30 days, while 20 only received ibuprofen. All statistical analyses were conducted using the Statistical Program for Social Sciences (IBM, Chicago, IL, USA). IL-8 levels increased in both groups (p=0.45). Visual Analog Scale (VAS) significantly decreased in the metformin group (p<0.001) but was not significant in the control group (p=0.06). Comparison of changes in IL-8 (p=0.13) and VAS (p=0.09) levels between the metformin and control groups was not statistically significant. This study suggests that the anti-diabetic drug metformin can also be used as an anti-inflammatory drug in adenomyosis patients as an adjunctive therapy. Further clinical trials need to be done on metformin drugs.
Downloads
Download data is not yet available.
Citations
Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Research 2019;8:F1000.
Guo SW. Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology. Reproduction 2022;164:R101-21.
Chen Q, Li YW, Wang S, et al. Clinical manifestations of adenomyosis patients with or without pain symptoms. J Pain Res 2019;12:3127-33.
Andersson JK, Khan Z, Weaver A, et al. Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: a pilot study. Acta Obstet Gynecol Scand 2019;98:1341-50.
Chen XC, Wu D, Wu H, et al. Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway. Lupus Sci Med 2022;9:e000611.
Ramanathan R, Firdous A, Dong Q, et al. Investigation into the anti-inflammatory properties of metformin in intervertebral disc cells. JOR Spine 2022;5:e1197.
Ali DES, Shah M, Ali A, et al. Treatment with metformin and combination of metformin plus pioglitazone on serum levels of IL-6 and IL-8 in polycystic ovary syndrome: a randomized clinical trial. Horm Metab Res 2019;51:714-22.
Baeza-Flores GDC, Guzmán-Priego CG, Parra-Flores LI, et al. Metformin: a prospective alternative for the treatment of chronic pain. Front Pharmacol 2020;11:558474.
Li W, Shao C, Liang J. Effects of shixiao huoxue decoction on pain, tumor necrosis factor-α, and interleukin-8 in patients with adenomyosis. Am J Transl Res 2024;16:584-91.
Hart PC, Kenny HA, Grassl N, et al. Mesothelial cell HIF1α expression is metabolically downregulated by metformin to prevent oncogenic tumor-stromal crosstalk. Cell Rep 2019;29:4086-98.e6.
Nguyen T, Ung TT, Li S, et al. Metformin inhibits lithocholic acid-induced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity. Scientific Reports 2019;9:2003.
Zhao C, Zheng L, Ma Y, et al. Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway. Int J Immunopathol Pharmacol 2024;38:03946320241249445.
Augusto PS, Braga AV, Rodrigues FF, et al. Metformin antinociceptive effect in models of nociceptive and neuropathic pain is partially mediated by activation of opioidergic mechanisms. Eur J Pharmacol 2019;858:172497.
Tsuji G, Hashimoto-Hachiya A, Yen VH, et al. Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis. Cell Death Discov 2020;6:11.
Gedikli E, Parlak M, Soydan AS. Effects of metformin on TNF-α release in lipopolysaccharide-induced monocytes in rats. CMJ 2024;46:29-34.
Cao J, Liu H, An Q, Han F. Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway. Nan Fang Yi Ke Da Xue Xue Bao 2023;43:1815-20. [Article in Chinese].
Petrovic A, Jovanovic I, Stojanovic B, et al. Harnessing metformin’s immunomodulatory effects on immune cells to combat breast cancer. Int J Mol Sci 2024;25:5869.
Deftu A, Chung PCS, Laedermann C, et al. The antidiabetic drug metformin regulates voltage-gated sodium channel NaV1.7 via the ubiquitin-ligase NEDD4-2. eNeuro 2022;9:ENEURO.0409-21.2022.
Kakhki FSH, Asghari A, Bardaghi Z, et al. The antidiabetic drug metformin attenuated depressive and anxietylike behaviors and oxidative stress in the brain in a rodent model of inflammation induced by lipopolysaccharide in male rats. Endocr Metab Immune Disord Drug Targets 202424:1525-37.
Bourdon M, Santulli P, Jeljeli M, et al. Immunological changes associated with adenomyosis: a systematic review. Hum Reprod Update 2021;27:108-29.
Karshikoff B, Martucci K, Mackey S. Relationship between blood cytokine levels, psychological comorbidity, and widespreadness of pain in chronic pelvic pain. Front Psychiatry 2021;12:651083.
Liu XN, Cheng ZP. Expression of high-mobility group box-1 in eutopic/ectopic endometrium and correlations with inflammation-related factors in adenomyosis. Gynecol Endocrinol 2023;39:2269265.
Rahmawati NY, Ahsan F, Santoso B, et al. IL-8 and IL-12p70 are associated with pelvic pain among infertile women with endometriosis. Pain Med 2023;24:1262-9.
Clower L, Fleshman T, Geldenhuys WJ, Santanam N. Targeting oxidative stress involved in endometriosis and its pain. Biomolecules 2022;12:1055.
Zhou Z, Guo Z, Lu X, Xu X. Mechanism of LDH and IL-8 Involved in pancreatic cancer pain and the correlation of pain degree. J Med Biochem 2024;43:664-70.
Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: mechanisms and pathogenesis. Semin Reprod Med 2020;38:129-43.
Nati ID, Malutan A, Ciortea R, et al. Exploring the influence of IL-8, IL-10, patient-reported pain, and physical activity on endometriosis severity. Diagnostics 2024;14:1822.
Ruan G, Xu J, Wang K, et al. Associations between serum IL-8 and knee symptoms, joint structures, and cartilage or bone biomarkers in patients with knee osteoarthritis. Clin Rheumatol 2019;38:3609-17.
Hedderson WC, Borsa P, Fillingim R, et al. Plasma concentrations of select inflammatory cytokines predicts pain intensity 48 hours post-shoulder muscle injury. Clin J Pain 2020;36:775-81.
Groote AD, Vyvere TV, Tjalma W, et al. Cytokine expression in cancer survivors suffering from chronic pain: a systematic review. Pain Physician 2024;27:E207-20.
Abduljabbar T, Vohra F, Ullah A, et al. Relationship between self-rated pain and peri-implant clinical, radiographic and whole salivary inflammatory markers among patients with and without peri-implantitis. Clin Implant Dent Relat Res 2019;21:1218-24.
Shu C, Yan D, Chen C, et al. Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways. Int Immunopharmacol 2019;74:105693.
Han Y, Yuan F, Deng C, et al. Metformin decreases LPS-induced inflammatory response in rabbit annulus fibrosus stem/progenitor cells by blocking HMGB1 release. Aging 2019;11:10252-65.
Kim JW, Kim SM, Park JS, et al. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren’s syndrome. Arthritis Res Ther 2019;21:136.
Repas J, Peternel L, Sourij H, Pavlin M. Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers in vitro. Front Endocrinol 2023;14:1216193.
Li Y, Gappy SS, Liu X, et al. 159 Metformin suppresses pro-inflammatory cytokines in vitreous of diabetes patients and human retinal vascular endothelium. PLoS One 2022;17:e0268451.
Wang F, Xin D, Meng X, Fan Q. Metformin downregulates PD-L1 expression in esophageal squamous cell carcinoma by inhibiting IL-6 signaling pathway. Dis Esophagus 2021;34:doab052.159.
Alimoradi N, Ramezani A, Tahami M, Firouzabadi N. Metformin exhibits anti-inflammatory effects by regulating microRNA-451/CXCL16 and B cell leukemia/lymphoma 2 in patients with osteoarthritis. ACR Open Rheumatol 2025;7:e11755.
Bai B, Chen H. Metformin: a novel weapon against inflammation. Front Pharmacol 2021;12:622262.
Nyambuya TM, Dludla P, Mxinwa V, et al. The impact of metformin and aspirin on T-cell mediated inflammation: A systematic review of in vitro and in vivo findings. Life Sci 2020;255:117854.
Salvatore T, Pafundi P, Galiero R, et al. Metformin: a potential therapeutic tool for rheumatologists. Pharmaceuticals 2020;13:234.
Xiong W, Sun K, Zhu Y, et al. Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. Cell Death Dis 2021;12:934.
Kristófi R, Eriksson JW. Metformin as an anti-inflammatory agent: a short review. J Endocrinol 2021;251:R11-22.
Sakata N. The anti-inflammatory effect of metformin: the molecular targets. Genes Cells 2024;29:183-91.
Na H, Kwon JY, Lee SY, et al. Metformin attenuates monosodium-iodoacetate-induced osteoarthritis via regulation of pain mediators and the autophagy–lysosomal pathway. Cells 2021;10:681.
Wei J, Wei Y, Huang M, et al. Is metformin a possible treatment for diabetic neuropathy? J Diabetes 2022;14:658-69.
Li H, Ding X, Terkeltaub R, et al. Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior. Arthritis Res Ther 2020;22:34.
Carvalho-E-Silva AP, Harmer AR, Ferreira ML, Ferreira PH. The effect of the anti-diabetic drug metformin on musculoskeletal pain: a cross-sectional study with 21,889 individuals from the UK biobank. Eur J Pain 2021;25:1264-73.
How to Cite
Metformin’s therapeutic potential in adenomyosis: insights from interleukin 8 level. (2025). Italian Journal of Medicine, 19(2). https://doi.org/10.4081/itjm.2025.1940
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.